Reposted by Amy McCart Reed
Exciting update to our #lobular breast cancer work with DNA repair and PARP inhibition, ahead of @sabcs.bsky.social next week! #oncosky #bcsm
www.biorxiv.org/content/10.1...
Despite lacking "BRCA-like" mutations and features, we find ILC models are sensitive to PARPi in vivo. Why? 🧵 1/n
biorxiv.org
Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast
Invasive lobular carcinoma of the breast (ILC) are typically estrogen receptor α (ER)-positive and present with biomarkers of anti-estrogen sensitive disease, yet patients with ILC face uniquely poor ...
